Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2004 Jul;63(7):797-803.
doi: 10.1136/ard.2003.014050.

Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial

H A Capell  1 , R Madhok, J A Hunter, D Porter, E Morrison, J Larkin, E A Thomson, R Hampson, F W Poon
Affiliations
Clinical Trial

Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial

H A Capell et al. Ann Rheum Dis. 2004 Jul.

Abstract

Background: Evidence for disease modifying activity of low dose corticosteroid treatment in rheumatoid arthritis is contradictory. Studies showing radiological benefit suggest that continued treatment is required to sustain the effect.

Objective: To evaluate the effect of low dose oral prednisolone in early rheumatoid arthritis on disease activity over two years.

Design: Double blind placebo controlled trial.

Methods: Patients with rheumatoid arthritis, duration <3 years (n = 167), were started on a disease modifying antirheumatic drug (DMARD; sulphasalazine) and allocated by stratified randomisation to prednisolone 7 mg/day or placebo. Primary outcome measure was radiological damage, assessed by the modified Sharp method. Clinical benefit was a secondary outcome. A proactive approach to identifying and treating corticosteroid adverse events was adopted. Patients who discontinued sulphasalazine were offered an alternative DMARD.

Results: 90 of 257 patients eligible for the study refused to participate (more women than men). Of those enrolled, 84% were seropositive for rheumatoid factor, median age 56 years, median disease duration 12 months, female to male ratio 1.8:1. Prednisolone was given to 84 patients; of these 73% continued prednisolone and 70% sulphasalazine at 2 years. Of the 83 patients on placebo, 80% continued placebo and 64% sulphasalazine at 2 years. There were no significant differences in radiological score or clinical and laboratory measures at 0 and 2 years.

Conclusions: Low dose prednisolone conferred no radiological or clinical benefit on patients maintained on a DMARD over two years. Low dose corticosteroids have no role in the routine management of rheumatoid arthritis treated with conventional disease modifying drugs.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow of participants through the WOSERACT study. FU, follow up; pred, prednisolone; SASP, sulphasalazine
Figure 2
Figure 2
Changes in total x ray score over two years. FWP, F W Poon (radiologist), chronological scoring; JH, J A Hunter (rheumatologist), random scoring.
See this image and copyright information in PMC

Comment in

References

    1. Ann Rheum Dis. 2002 Jan;61(1):32-6 - PubMed
    1. Lancet. 1999 Jan 23;353(9149):259-66 - PubMed
    1. Lancet. 1997 Aug 2;350(9074):309-18 - PubMed
    1. J Rheumatol. 1982 Sep-Oct;9(5):789-93 - PubMed
    1. Rheumatology (Oxford). 2001 Dec;40(12):1375-83 - PubMed

Publication types

MeSH terms